Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre-Reference-Cited by-同舟云学术

Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre

Published:2020-12 Issue: Volume:150 Page:195-200
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Marshall Kelly,Jackson Susan,Jones Jennifer,Holme Jayne,Lyons Judith,Barrett Emma,Taylor Paul,Bishop Paul,Hodgson Clare,Green Michael,Telford Nicholas,Evison Matthew

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference13 articles.

1. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach;Nicholson;J. Thorac. Oncol.,2020

2. Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology

3. Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples;Monaco;Adv. Anat. Pathol.,2018

4. RCoPNLC. Spotlight Report on Molecular Testing in Advanced Lung Cancer;Audit,2020

5. A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations;Ali;Oncol. Lett.,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas;Translational Lung Cancer Research;2024-04

2. Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues;BMJ Case Reports;2024-02

3. Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment;Annual Review of Pathology: Mechanisms of Disease;2024-01-24

4. Updates in Management of Malignant Pleural Mesothelioma;Current Treatment Options in Oncology;2023-11-17

5. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study;Lung Cancer;2023-01